Edap Tms (NASDAQ:EDAP) Given New $10.00 Price Target at HC Wainwright

Edap Tms (NASDAQ:EDAP) had its price target dropped by research analysts at HC Wainwright from $14.00 to $10.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the medical equipment provider’s stock. HC Wainwright’s price target would suggest a potential upside of 201.20% from the stock’s previous close.

A number of other research firms have also commented on EDAP. Wall Street Zen lowered shares of Edap Tms from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Edap Tms in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $6.00.

Edap Tms Trading Down 1.5%

Edap Tms stock traded down $0.05 during midday trading on Thursday, reaching $3.32. The stock had a trading volume of 4,680 shares, compared to its average volume of 64,757. The firm’s fifty day simple moving average is $4.14 and its two-hundred day simple moving average is $3.22. Edap Tms has a twelve month low of $1.21 and a twelve month high of $5.05. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.19. The firm has a market cap of $124.13 million, a price-to-earnings ratio of -4.31 and a beta of -0.09.

Edap Tms (NASDAQ:EDAP) last posted its quarterly earnings data on Wednesday, March 25th. The medical equipment provider reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.09). Edap Tms had a negative return on equity of 100.07% and a negative net margin of 41.24%.The firm had revenue of $22.22 million during the quarter, compared to analyst estimates of $21.28 million. Equities analysts anticipate that Edap Tms will post -0.6 EPS for the current fiscal year.

Institutional Investors Weigh In On Edap Tms

A number of institutional investors have recently modified their holdings of the stock. Rock Springs Capital Management LP boosted its stake in shares of Edap Tms by 1.3% during the 4th quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the medical equipment provider’s stock valued at $4,233,000 after buying an additional 16,500 shares during the period. Flax Pond Capital LLC acquired a new stake in shares of Edap Tms during the 4th quarter valued at $2,623,000. Leonteq Securities AG acquired a new stake in shares of Edap Tms during the 4th quarter valued at $313,000. Kovack Advisors Inc. acquired a new stake in shares of Edap Tms during the 4th quarter valued at $53,000. Finally, Financial Planning Navigators CORP acquired a new stake in shares of Edap Tms during the 4th quarter valued at $33,000. Institutional investors and hedge funds own 62.74% of the company’s stock.

Edap Tms Company Profile

Edap Tms SA (NASDAQ: EDAP) is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm’s core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms’s Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.

Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.